Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants.

The document shows that this resale involves company-issued shares that have not yet been traded on the public market, aiming to provide liquidity for existing shareholders. As a clinical-stage company focused on innovation in tumor treatment, Tempest Therapeutics' share resale plan has attracted market attention. Industry analysts note that such financing activities are usually closely related to the progress of corporate R&D and capital needs. According to SEC disclosure requirements, the prospectus details key information such as the number of shares, resale conditions, and warrant exercise terms.